Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT

Ryan M Phillips; Michael A Gorin; Steven P Rowe; Martin G Pomper; Kenneth J Pienta; Ashley E Ross; Phuoc T Tran

doi:10.1016/j.eucr.2017.11.021

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT

Urol Case Rep. 2017 Nov 22:16:86-88. doi: 10.1016/j.eucr.2017.11.021. eCollection 2018 Jan.

Authors

Ryan M Phillips¹, Michael A Gorin^{2

3}, Steven P Rowe^{2

3}, Martin G Pomper^{2

3}, Kenneth J Pienta^{2

4}, Ashley E Ross², Phuoc T Tran^{1

2

4}

Affiliations

¹ Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁴ Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

No abstract available

Keywords: 103Pd, palladium-103, Gy, gray; 18F-DCFPyL, 2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid; 99mTC, technetium 99m; ADT, androgen deprivation therapy; CT, computed tomography; Local recurrence; MRI, magnetic resonance imaging; Molecular imaging; PET, positron emission tomography; PSA, prostate-specific antigen; PSMA; PSMA, prostate-specific membrane antigen; Prostate cancer; Radiotherapy; SABR, stereotactic ablative radiotherapy; SUVmax, maximum standardized uptake value.

Publication types

Case Reports

Grants and funding

R01 CA166348/CA/NCI NIH HHS/United States